Krystal BiotechKRYS
KRYS
About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Employees: 275
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $63.3M | Put options by funds: $36.8M
0% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]
2% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 96
1.04% less ownership
Funds ownership: 97.58% [Q3] → 96.55% (-1.04%) [Q4]
6% less funds holding
Funds holding: 279 [Q3] → 262 (-17) [Q4]
15% less capital invested
Capital invested by funds: $5.1B [Q3] → $4.35B (-$753M) [Q4]
24% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 50
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$215
27%
upside
Avg. target
$227
33%
upside
High target
$245
44%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target | 41%upside $240 | Buy Maintained | 29 Apr 2025 |
Jefferies Roger Song 16% 1-year accuracy 3 / 19 met price target | 44%upside $245 | Buy Initiated | 5 Mar 2025 |
Citigroup Yigal Nochomovitz 20% 1-year accuracy 8 / 41 met price target | 27%upside $215 | Neutral Maintained | 20 Feb 2025 |
Cantor Fitzgerald Josh Schimmer 25% 1-year accuracy 14 / 55 met price target | 27%upside $215 | Overweight Reiterated | 20 Feb 2025 |
Chardan Capital Geulah Livshits 10% 1-year accuracy 6 / 59 met price target | 28%upside $218 | Buy Maintained | 20 Feb 2025 |
Financial journalist opinion
Based on 5 articles about KRYS published over the past 30 days
Neutral
Zacks Investment Research
1 day ago
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
2 days ago
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to address the genetic root cause of DEB by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing.
Neutral
GlobeNewsWire
6 days ago
Krystal Biotech to Present at Upcoming Scientific Conferences
PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.
Neutral
GlobeNewsWire
3 weeks ago
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth has also served as a valuable contributor on Jeune's board of directors since February 2021.
Neutral
Zacks Investment Research
3 weeks ago
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Positive
Seeking Alpha
1 month ago
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuation, its growth potential, strong financials, and first-mover advantage justify the market's appraisal, with a fair value estimate of $175-$185 per share. Key risks include regulatory setbacks, reimbursement issues, competition from Abeona's EB-101, and high operational expenses, which could impact short-term valuation and cash flow.
Positive
Zacks Investment Research
1 month ago
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Positive
Zacks Investment Research
1 month ago
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 month ago
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
Positive
Zacks Investment Research
1 month ago
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
Charts implemented using Lightweight Charts™